Israeli team develops 'anti-diabetes drug'
463 million people have been diagnosed with diabetes worldwide
and up to 95% of this number have Type 2.

Concenter BioPharma is a subsidiary of Silkim Pharma Ltd., which developed a novel, protected PLATFORM of drugs for proven treatments of multiple indications.
Our PLATFORM is the result of extensive investigation of animal models of human diseases.